AN2

MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet…

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung diseasePhase 2/3 pivotal trial…

A cocktail of two monoclonal antibodies against COVID-19, casirivimab and imdevimab, reduced hospitalization and death by 71% versus placebo in high-risk, non-hospitalized patients,…